TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33792729

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) 1500 IU for patients ≤60 kg and 2000 IU for patients >60 kg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Frozen Plasma (FP) 3 U for patients ≤60 kg and 4 U for patients >60 kg
Number of subjects: 101
Study: 32035876

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of XueShuanTong (150 mg/person)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous infusion of XueShuanTong (150 mg/person)
Number of subjects: 0
Study: 36201819

Group type: EXPERIMENTAL
Intervention: Teacher classroom management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34639560

Group type: EXPERIMENTAL
Intervention: Concurrent Resistance Training (CRT) program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual training (Control Group)
Number of subjects: 22
Study: 32367309

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0
Study: 35029590

Group type: EXPERIMENTAL
Intervention: 15 weeks of resistance exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls (CON)
Number of subjects: 40
Study: 32048134

Group type: EXPERIMENTAL
Intervention: Sn150 kVp group (1/2th radiation dose level/150 kVp with a tin filter/2.34 mGy)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sn100 kVp group (1/10th radiation dose level/100 kVp with a tin filter/0.47 mGy)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 120 kVp group (standard radiation dose/tube voltage, 120 kVp/CT volume dose index, 4.68 mGy)
Number of subjects: 150
Study: 35849051

Group type: EXPERIMENTAL
Intervention: Occupational therapy using Ayres Sensory Integration
Number of subjects: 17

Group type: COMPARATOR
Intervention: Usual therapeutic and educational services
Number of subjects: 17
Study: 33047971

Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI‐guided parathyroidectomy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Total parathyroidectomy plus forearm transplantation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 67
Study: 35395815

Group type: EXPERIMENTAL
Intervention: Resistance garment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Running shorts (control)
Number of subjects: 15
Study: 33174528

Group type: EXPERIMENTAL
Intervention: Antimicrobial-impregnated peripherally inserted central venous catheter (coated with rifampicin-miconazole)
Number of subjects: 861

Group type: COMPARATOR
Intervention: Standard peripherally inserted central venous catheter
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Antimicrobial-impregnated peripherally inserted central venous catheter
Number of subjects: 861
Study: 35198576

Group type: COMPARATOR
Intervention: Group RD1: 20 mL of 0.5% ropivacaine with 5 mg of dexamethasone and 0.5 μg·kg−1 DEX
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Group RD2: 20 mL of 0.5% ropivacaine with 5 mg of dexamethasone and 1 μg·kg−1 DEX
Number of subjects: 95
Study: 32945777

Group type: EXPERIMENTAL
Intervention: Positive psychology intervention
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Wearable wrist sensors
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Health care utilization data
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 166
Study: 32272848

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with SAPIEN 3 valve
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 1000
Study: 35229220

Group type: EXPERIMENTAL
Intervention: Medication group (Paracetamol given 1 hour before debonding)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Finger pressure group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Stress relief group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study: 36223862

Group type: EXPERIMENTAL
Intervention: Video recording of performance with verbal feedback
Number of subjects: 23

Group type: COMPARATOR
Intervention: Verbal feedback only (Control)
Number of subjects: 23
Study: 33871240

Group type: EXPERIMENTAL
Intervention: Combined exercises (ten-week incremental endurance-resistance training, three sessions a week)
Number of subjects: 24
Study: 32729222

Group type: EXPERIMENTAL
Intervention: Combination therapy with pioglitazone plus weekly exenatide
Number of subjects: 331

Group type: COMPARATOR
Intervention: Basal/bolus insulin therapy
Number of subjects: 331
Study: 35193665

Group type: EXPERIMENTAL
Intervention: Tengfu Jiangya tablet (TJT) combined with valsartan/amlodipine (Val/Aml) 80/5 mg
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo combined with valsartan/amlodipine (Val/Aml) 80/5 mg
Number of subjects: 288
Study: 33664472

Group type: EXPERIMENTAL
Intervention: sucrose 24% liquid with non‐nutritive sucking
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: sucrose 24% gel with non‐nutritive sucking
Number of subjects: 195

Group type: COMPARATOR
Intervention: breastfeeding
Number of subjects: 195
Study: 32631651

Group type: EXPERIMENTAL
Intervention: Semiautomatic needle segmentation algorithm
Number of subjects: 7

Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 7
Study: 33433559

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 49331

Group type: COMPARATOR
Intervention: Usual activity comparison (Control)
Number of subjects: 49331
Study: 32819680

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with Defibrillator (CRT-D)
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Implantable Cardiac Defibrillator (ICD)
Number of subjects: 1381

Group type: EXPERIMENTAL
Intervention: 6MWT
Number of subjects: 1381
Study: 36038181

Group type: COMPARATOR
Intervention: BDQ, Pa and LZD 600 mg daily for 26 weeks (Control arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDQ, Pa and LZD 600 mg for 9 weeks followed by 300 mg for 17 weeks (Intervention arm 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDQ, Pa and LZD 600 mg for 13 weeks followed by 300 mg for 13 weeks (Intervention arm 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All arms (including control)
Number of subjects: 0
Study: 34412146

Group type: EXPERIMENTAL
Intervention: Pattern-oriented approaches using multivariate data analysis on chromatographic/spectroscopic fingerprints
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional approaches for quality control of herbal medicines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic methods for plant material/plant extract authentication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compound-oriented approach
Number of subjects: 0
Study: 33483776

Group type: EXPERIMENTAL
Intervention: Focused electromagnetic high‐energetic ESWT (2000 shots, 3 Hz, 0.35 mJ/mm2/hand, Storz Duolith SD1, n = 27)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo ESWT (2000 shots, 3 Hz, 0.01 mJ/mm2/hand, n = 25)
Number of subjects: 52
Study: 32008396

Group type: EXPERIMENTAL
Intervention: CBT‐GSH plus Noom Monitor
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 225
Study: 36972286

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg (single dose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Celecoxib 200 mg (single dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg (four-fold dose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Celecoxib 200 mg (four-fold dose)
Number of subjects: 15
Study: 33063412

Group type: EXPERIMENTAL
Intervention: Telemedical intervention (TM) using non-invasive devices for daily monitoring of electrocardiogram, blood pressure, and body weight; duration: 12 months.
Number of subjects: 710

Group type: COMPARATOR
Intervention: Usual care (UC); duration: 12 months.
Number of subjects: 710
Study: 32381820

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methyl cellulose (Control)
Number of subjects: 30
Study: 35810769

Group type: EXPERIMENTAL
Intervention: pTBI + hNSCs at maximum tolerated dose (MTD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: pTBI + vehicle
Number of subjects: 40
Study: 33262230

Group type: EXPERIMENTAL
Intervention: High-intensity progressive aerobic exercise (PAE) for 24 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Waitlist group (habitual lifestyle)
Number of subjects: 86
Study: 36343653

Group type: EXPERIMENTAL
Intervention: Personalised cooler dialysate (mean dialysate temperature 35·8°C)
Number of subjects: 15413

Group type: COMPARATOR
Intervention: Standard temperature dialysate (36·5°C)
Number of subjects: 15413

Group type: EXPERIMENTAL
Intervention: Personalised cooler dialysate
Number of subjects: 15413

Group type: COMPARATOR
Intervention: Standard temperature dialysate
Number of subjects: 15413
Study: 32086787

Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy (DAPT)
Number of subjects: 3009
Study: 32238172

Group type: EXPERIMENTAL
Intervention: UA-ADRCs (11.4 × 10^6 cells in 5 mL liquid; mean cell viability: 88%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Corticosteroid injection (80 mg of methylprednisolone plus 3 mL of 0.25% bupivacaine)
Number of subjects: 16
Study: 34868484

Group type: EXPERIMENTAL
Intervention: Online Narrative Exposure Therapy (eNET) - 8-12 sessions of 90 minutes each conducted via video calls with trained paraprofessionals.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control group receiving the same intervention after a three-month wait period.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: eNET intervention
Number of subjects: 50
Study: 33958864

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 136
Study: 32075845

Group type: EXPERIMENTAL
Intervention: Supplement combination containing Boswellia serrata extract, pine bark extract, methylsulfonylmethane, and curcumin
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Supplement combination
Number of subjects: 106
Study: 616121612

Group type: EXPERIMENTAL
Intervention: 15-mm Jupiter scleral lens worn for 2 hours
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control eye (no lens worn)
Number of subjects: 26
Study: 36375147

Group type: EXPERIMENTAL
Intervention: Total Ankle Replacement (TAR)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Ankle Fusion (AF)
Number of subjects: 303
Study: 33638918

Group type: EXPERIMENTAL
Intervention: Respiration chamber tests
Number of subjects: 30

Group type: COMPARATOR
Intervention: Face mask tests
Number of subjects: 30
Study: 32153793

Group type: EXPERIMENTAL
Intervention: NT‐proBNP ≥900 ng/L
Number of subjects: 93
Study: 35781768

Group type: EXPERIMENTAL
Intervention: Population-Screening (PS)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Family-History (FH)
Number of subjects: 1034
Study: 33796978

Group type: EXPERIMENTAL
Intervention: High-risk adolescents (15% highest scoring on SDQ-Y)
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Low-risk adolescents (85% lowest scoring on SDQ-Y)
Number of subjects: 1022
Study: 32152495

Group type: EXPERIMENTAL
Intervention: Maternal antidepressant use during pregnancy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no antidepressant use)
Number of subjects: 120
Study: 35237948

Group type: EXPERIMENTAL
Intervention: Treadmill-based gait slip training (N = 73), 40 unpredictable treadmill slips
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (N = 70), walked on a treadmill at comfortable speed
Number of subjects: 143
Study: 32268649

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention combining clinical preventive services and lifestyle adjustment
Number of subjects: 3706

Group type: COMPARATOR
Intervention: Routine chronic disease management (Control)
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 3706
Study: 35345983

Group type: EXPERIMENTAL
Intervention: Participatory heat education intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study: 33954997

Group type: EXPERIMENTAL
Intervention: Semi-compliant balloon (SCB)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Non-compliant balloon (NCB)
Number of subjects: 251
Study: 32382556

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (DEX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral midazolam (MID)
Number of subjects: 60
Study: 36631889

Group type: EXPERIMENTAL
Intervention: NICC (Novel Integrated Care Concept)
Number of subjects: 960

Group type: COMPARATOR
Intervention: SoC (Standard of Care)
Number of subjects: 960
Study: 33486150

Group type: EXPERIMENTAL
Intervention: CT/US
Number of subjects: 600

Group type: COMPARATOR
Intervention: US
Number of subjects: 600

Group type: COMPARATOR
Intervention: CT
Number of subjects: 600

Group type: COMPARATOR
Intervention: CT, US, CT/US
Number of subjects: 600
Study: 32389012

Group type: EXPERIMENTAL
Intervention: Qinzhuliangxue decoction (QZLXD)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Runzaozhiyang capsules (RZZYC)
Number of subjects: 176
Study: 35421954

Group type: EXPERIMENTAL
Intervention: PTEBL teaching method combined with Caesar (trauma patient simulator)
Number of subjects: 78
Study: 34795312

Group type: EXPERIMENTAL
Intervention: Precautionary behaviours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public confidence in government
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological fatigue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 0
Study: 32830802

Group type: EXPERIMENTAL
Intervention: Serious game for Symptom Self‐Management Training for Chemotherapy-Induced Nausea and Vomiting (CINV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Serious game
Number of subjects: 80
Study: 35816716

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ): 140 mL; ∼8 mmol nitrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prune juice (CON): 166 mL; < 0.01 mmol nitrate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prune juice (CON)
Number of subjects: 20
Study: 32826167

Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cells injection with standard diabetic wound care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard diabetic wound care
Number of subjects: 20
Study: 35211042

Group type: EXPERIMENTAL
Intervention: Bumetanide (max 1 mg twice daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 38
Study: 33153062

Group type: EXPERIMENTAL
Intervention: Low-Intensity Internet-Based Intervention focused on promoting Positive Affect
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 56
Study: 35303094

Group type: EXPERIMENTAL
Intervention: Cathodal HD tDCS targeting left DLPFC
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cathodal HD tDCS targeting left IFG
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham cathodal HD tDCS
Number of subjects: 67
Study: 32767565

Group type: EXPERIMENTAL
Intervention: Titanium curettes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Chitosan brushes
Number of subjects: 44
Study: 33034052

Group type: EXPERIMENTAL
Intervention: DDGP combined with RT
Number of subjects: 65

Group type: COMPARATOR
Intervention: RT
Number of subjects: 65
Study: 33007709

Group type: EXPERIMENTAL
Intervention: NiPPV (bilevel mode - Astral 150)
Number of subjects: 14
Study: 33527182

Group type: EXPERIMENTAL
Intervention: 20G IAC
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: 22G IAC
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: 24G IAC
Number of subjects: 353
Study: 33957299

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation (O2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Medical air (Control)
Number of subjects: 9
Study: 32747990

Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 302
Study: 34796595

Group type: EXPERIMENTAL
Intervention: Microneedling
Number of subjects: 40

Group type: COMPARATOR
Intervention: CO2 fractional laser
Number of subjects: 40
Study: 32979383

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 98

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 98
Study: 33199437

Group type: EXPERIMENTAL
Intervention: Active NBM‐DBS
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham NBM‐DBS
Number of subjects: 6
Study: 36409489

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/d)
Number of subjects: 251
Study: 34446756

Group type: EXPERIMENTAL
Intervention: Total sleep time (TST)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: PSQI global score
Number of subjects: 164
Study: 34608858

Group type: EXPERIMENTAL
Intervention: Newer nonwearable device (Beddit 3.5)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Early version of the nonwearable device (Beddit 3.0)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Clinical-grade actigraphy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Self-reported sleep measures
Number of subjects: 35
Study: 34289971

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (used on ≥2 occasions)
Number of subjects: 5174

Group type: COMPARATOR
Intervention: No use or a single report of oral antibiotics
Number of subjects: 5174
Study: 34973967

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Air Insufflation (C)
Number of subjects: 245
Study: 32030880

Group type: EXPERIMENTAL
Intervention: Microneedling with tacrolimus
Number of subjects: 90

Group type: COMPARATOR
Intervention: Microneedling only
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 90
Study: 35443387

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (97mg-valsartan 103mg)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Ramipril (5mg twice daily)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Number of subjects: 566

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 566
Study: 33678596

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 33
Study: 32946924

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG; 10 mg/kg)
Number of subjects: 54
Study: 36183733

Group type: EXPERIMENTAL
Intervention: Fulvestrant (500 mg intramuscularly on day 1 of each 28‐day cycle and on day 15 of cycle 1) and palbociclib (125 mg orally once per day on days 1‐21 of a 28‐day cycle)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Aromatase inhibitor (2·5 mg letrozole, 1 mg anastrozole, or 25 mg exemestane, orally once per day, taken continuously) and palbociclib (125 mg orally once per day on days 1‐21 of a 28‐day cycle)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 172

Group type: COMPARATOR
Intervention: Aromatase inhibitor and palbociclib group
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Fulvestrant and palbociclib group
Number of subjects: 172
Study: 33793753

Group type: EXPERIMENTAL
Intervention: Reinforced stapling
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard stapling
Number of subjects: 106
Study: 33129609

Group type: EXPERIMENTAL
Intervention: AV7909 (three doses at Days 1, 15, and 29)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: AV7909 (two doses at Days 1 and 29)
Number of subjects: 305

Group type: COMPARATOR
Intervention: BioThrax
Number of subjects: 305
Study: 34985171

Group type: COMPARATOR
Intervention: Brief Advice (BA)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Rate Reduction (RR)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Combined MI and Rate Reduction (MI+RR)
Number of subjects: 903
Study: 34304438

Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg/d)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/d)
Number of subjects: 200
Study: 32650518

Group type: EXPERIMENTAL
Intervention: Trimebutine maleate (TM) 300 mg twice per day (BID) for 4 weeks
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo BID for 4 weeks
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Trimebutine maleate (TM)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 34857226

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (3680 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: n-3 PUFA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 34672349

Group type: EXPERIMENTAL
Intervention: Intravenous trabectedin (1.5 mg/m2 every 3 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Local standard of care (LOC)
Number of subjects: 90
Study: 33080817

Group type: EXPERIMENTAL
Intervention: Velocity-monitored resistance training (RT) with a velocity loss of 20%, 2 sessions per week for 10 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (CG) maintaining daily routine
Number of subjects: 39
Study: 33482048

Group type: EXPERIMENTAL
Intervention: Depression Scale for Children
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: UCLA Loneliness Scale
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Linear regression analysis for depression and UCLA loneliness score
Number of subjects: 535
Study: 33324478

Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation (auto‐HSCT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Intensive cytarabine‐based chemotherapy
Number of subjects: 101
Study: 32743763

Group type: EXPERIMENTAL
Intervention: Dietary zinc intake
Number of subjects: 142
Study: 35865342

Group type: EXPERIMENTAL
Intervention: Qinpi Tongfeng Formula (QPTFF)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Diclofenac sodium sustained-release tablets
Number of subjects: 114
Study: 32387499

Group type: EXPERIMENTAL
Intervention: Pancreaticobiliary (BP) master system for EUS training
Number of subjects: 0
Study: 34935760

Group type: EXPERIMENTAL
Intervention: Initial levels of cancer-related stress (T1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Initial levels of IL-6 (T1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dropping social roles over time (T1 to T3)
Number of subjects: 120